FDA fully approves 'novel' Alzheimer’s disease drug Leqembi

The Food and Drug Administration (FDA) has fully approved a “novel” drug used to treat adult patients with Alzheimer’s, the agency announced. Leqembi, which is produced by Japanese drugmaker Eisai and American-based drugmaker Biogen, was initially approved in January under the Accelerated Approval